• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

The role of tobacco cessation, antiplatelet and lipid-lowering therapies in the treatment of peripheral arterial disease.

作者信息

Hirsch A T, Treat-Jacobson D, Lando H A, Hatsukami D K

机构信息

Minnesota Vascular Diseases Center, University of Minnesota Medical School, Minneapolis 55455, USA.

出版信息

Vasc Med. 1997;2(3):243-51. doi: 10.1177/1358863X9700200314.

DOI:10.1177/1358863X9700200314
PMID:9546975
Abstract

Despite the widely held belief that there are no effective medical therapies for peripheral arterial disease (PAD), current data suggest that medical therapies can effectively modify the natural history of atherosclerotic lower extremity arterial occlusive disease. The ideal medical therapy would improve claudication, forestall the onset of limb-threatening events, decrease rates of invasive interventional therapies and improve long-term patient survival. These ideal outcomes might be achieved through the use of smoking cessation interventions, including behavioral and pharmacological therapy, and the administration of antiplatelet and lipid-lowering medications in patients with PAD.

摘要

相似文献

1
The role of tobacco cessation, antiplatelet and lipid-lowering therapies in the treatment of peripheral arterial disease.
Vasc Med. 1997;2(3):243-51. doi: 10.1177/1358863X9700200314.
2
Contemporary and optimal medical management of peripheral arterial disease.外周动脉疾病的当代最佳医学管理。
Surg Clin North Am. 2013 Aug;93(4):761-78, vii. doi: 10.1016/j.suc.2013.04.009. Epub 2013 Jun 18.
3
Medical and lifestyle management of peripheral arterial disease.外周动脉疾病的医学与生活方式管理
J Vasc Surg. 2018 Nov;68(5):1595-1606. doi: 10.1016/j.jvs.2018.07.027.
4
Management of peripheral arterial disease and intermittent claudication.外周动脉疾病与间歇性跛行的管理
J Am Board Fam Pract. 2001 Nov-Dec;14(6):443-50.
5
Pharmacologic therapy for peripheral arterial disease and claudication.外周动脉疾病和间歇性跛行的药物治疗
J Vasc Surg. 2002 Dec;36(6):1283-91. doi: 10.1067/mva.2002.129654.
6
Pharmacologic risk factor treatment of peripheral arterial disease is lacking and requires vascular surgeon participation.外周动脉疾病的药物风险因素治疗尚不完善,需要血管外科医生的参与。
Ann Vasc Surg. 2007 Mar;21(2):163-6. doi: 10.1016/j.avsg.2007.01.008.
7
Pharmacologic risk factor management in peripheral arterial disease: a vade mecum for vascular surgeons.外周动脉疾病的药物风险因素管理:血管外科医生手册
J Vasc Surg. 2008 May;47(5):1108-15. doi: 10.1016/j.jvs.2007.12.033. Epub 2008 Apr 18.
8
Intermittent claudication due to peripheral artery disease: best modern medical and endovascular therapeutic approaches.外周动脉疾病所致间歇性跛行:最佳现代医学及血管内治疗方法
Curr Cardiol Rep. 2015 Oct;17(10):86. doi: 10.1007/s11886-015-0643-3.
9
What constitutes best medical therapy for peripheral arterial disease?什么是外周动脉疾病的最佳药物治疗方案?
Eur J Vasc Endovasc Surg. 2002 Jul;24(1):6-12. doi: 10.1053/ejvs.2002.1684.
10
Pharmacological interventions for peripheral artery disease.外周动脉疾病的药物干预措施。
Expert Opin Pharmacother. 2007 Jul;8(10):1465-77. doi: 10.1517/14656566.8.10.1465.

引用本文的文献

1
Clinical Characteristics and Current Practice of Endovascular Revascularization in Aorto-Iliac, Femoropopliteal and Infra-Popliteal Lower Extremity Artery Disease-Insights from the RECCORD Registry.主-髂、股腘及腘以下下肢动脉疾病血管内血运重建的临床特征与当前实践——来自RECCORD注册研究的见解
J Clin Med. 2022 Oct 14;11(20):6074. doi: 10.3390/jcm11206074.
2
[Medication-based secondary prevention in patients with peripheral arterial occlusive disease : An analysis based on secondary data].外周动脉闭塞性疾病患者基于药物的二级预防:基于二次数据的分析
Herz. 2021 Sep;46(Suppl 2):280-286. doi: 10.1007/s00059-020-04998-w. Epub 2020 Nov 18.
3
On the Cutting Edge: Wound Care for the Endovascular Specialist.
前沿资讯:血管腔内介入专家的伤口护理
Semin Intervent Radiol. 2018 Dec;35(5):406-426. doi: 10.1055/s-0038-1676342. Epub 2019 Feb 5.
4
[Not Available].[无可用内容]
Internist (Berl). 2000 Nov;41(12):1416-1422. doi: 10.1007/s001080050709.
5
The anti-microbial peptide SR-0379 stimulates human endothelial progenitor cell-mediated repair of peripheral artery diseases.抗菌肽 SR-0379 可刺激人内皮祖细胞修复外周动脉疾病。
BMB Rep. 2017 Oct;50(10):504-509. doi: 10.5483/bmbrep.2017.50.10.043.
6
A single bout of resistance exercise does not modify cardiovascular responses during daily activities in patients with peripheral artery disease.单次抗阻运动不会改变外周动脉疾病患者日常活动期间的心血管反应。
Blood Press Monit. 2014 Apr;19(2):64-71. doi: 10.1097/MBP.0000000000000022.
7
Critical limb ischemia: advanced medical therapy.严重肢体缺血:先进的药物治疗
Methodist Debakey Cardiovasc J. 2012 Oct-Dec;8(4):3-9. doi: 10.14797/mdcj-8-4-3.
8
Pharmacological treatment of patients with peripheral arterial disease.外周动脉疾病患者的药物治疗。
Drugs. 2003;63(7):637-47. doi: 10.2165/00003495-200363070-00002.
9
Management of peripheral arterial disease in primary care.基层医疗中周围动脉疾病的管理
BMJ. 2003 Mar 15;326(7389):584-8. doi: 10.1136/bmj.326.7389.584.
10
Measuring treatment effects of cilostazol on clinical trial endpoints in patients with intermittent claudication.衡量西洛他唑对间歇性跛行患者临床试验终点的治疗效果。
Clin Cardiol. 2002 Mar;25(3):91-4. doi: 10.1002/clc.4960250303.